<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621683</url>
  </required_header>
  <id_info>
    <org_study_id>J298384255</org_study_id>
    <nct_id>NCT03621683</nct_id>
  </id_info>
  <brief_title>Antioxidants vs. Ovarian Bio-stimulation Therapy to Rescue the Ovarian Reserve</brief_title>
  <official_title>Antioxidants vs.Ovarian Bio-stimulation Therapy to Rescue the Ovarian Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lucy Coleman</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fertiaguerrevere</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two group of patients were selected. Group 1 represents 46 patients that received
      ovarian-biostimulation monthly for three months. Group 2 represents 32 patients that received
      antioxidant therapy daily for 3 months. Results are noted and analysed.

      Both groups represent patients with procedures already ongoing, and with diagnosed poor or
      depleted ovarian reserve.

      The analysis has been made to compare the efficacy of both procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bioestimulation group received a blood rich platelet therapy monthly for three months,
      with a technique developed by the laboratory. The second group of antioxidants received a
      combination of antioxidants monthly for three months. Both groups were compared to assess the
      results in terms of ovarian response (number of astral follicles, AMH levels, FSH, LH), and
      egg quality, embryo development, implantation rate, and successful pregnancy with healthy
      live birth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2016</start_date>
  <completion_date type="Actual">August 28, 2017</completion_date>
  <primary_completion_date type="Actual">January 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective comparative study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>variation of hormones FSH and LH directly involved with ovarian reserve</measure>
    <time_frame>18 months</time_frame>
    <description>Both groups are compared after bio-stimulation and antioxidant therapy is performed to access any possible changes with FSH-LH post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>variation of AMH directly involved with ovarian reserve in both groups</measure>
    <time_frame>18 months</time_frame>
    <description>Both groups are compared after bio-stimulation and antioxidant therapy is performed to access any possible changes with AMH values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>variation in recruitment of antral follicles in both groups</measure>
    <time_frame>18 months</time_frame>
    <description>Both groups are compared after bio-stimulation and antioxidant therapy is performed to access any possible changes with the number of astral follicles available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of good quality eggs obtained in both groups after IVF</measure>
    <time_frame>18 months</time_frame>
    <description>Egg quality is evaluated in both group of women undergoing IVF after bio-stimulation or antioxidant therapy are performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and quality of fertilised eggs obtained in both groups after IVF</measure>
    <time_frame>18 months</time_frame>
    <description>the number and quality of fertilised eggs is evaluated in both groups of women undergoing IVF after bio-stimulation or antioxidant therapy is performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>ovarian bio-stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
ovarian bio-stimulation: blood rich plasma platelets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidant therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention:
antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood rich plasma platelets</intervention_name>
    <description>Injection of blood rich platelet into the ovaries.</description>
    <arm_group_label>Antioxidant therapy</arm_group_label>
    <arm_group_label>ovarian bio-stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antioxidant therapy</intervention_name>
    <description>Antioxidants:
Q10, DHEA, Vitamina E, Vitamin C, Omega 3</description>
    <arm_group_label>Antioxidant therapy</arm_group_label>
    <arm_group_label>ovarian bio-stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 38 and 46 years

          -  FSH&gt; 12 mIU

          -  Estradiol &gt; 100 pg/ml

          -  AMH &lt; 0.8 ng/mL

        Exclusion Criteria:

          -  Pelvic inflammatory syndrome

          -  vaginal pathologies

          -  known history of hyperandrogenism

          -  diagnosed platelet disorders as adhesion

          -  aggregation

          -  disorder of thromboxane synthesis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical staff</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fertiaguerrevere Fertility</name>
      <address>
        <city>Caracas</city>
        <state>Disfrito Federal</state>
        <zip>1018</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <results_reference>
    <citation>Bhartiya D, Parte S, Patel H, Sriraman K, Zaveri K, Hinduja I. Novel Action of FSH on Stem Cells in Adult Mammalian Ovary Induces Postnatal Oogenesis and Primordial Follicle Assembly. Stem Cells Int. 2016;2016:5096596. doi: 10.1155/2016/5096596. Epub 2015 Nov 9. Review.</citation>
    <PMID>26635884</PMID>
  </results_reference>
  <results_reference>
    <citation>Telfer EE. Germline stem cells in the postnatal mammalian ovary: a phenomenon of prosimian primates and mice? Reprod Biol Endocrinol. 2004 May 18;2:24.</citation>
    <PMID>15149546</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004 Mar 11;428(6979):145-50. Erratum in: Nature. 2004 Aug 26;430(7003):1062.</citation>
    <PMID>15014492</PMID>
  </results_reference>
  <results_reference>
    <citation>Pan Z, Sun M, Liang X, Li J, Zhou F, Zhong Z, Zheng Y. The Controversy, Challenges, and Potential Benefits of Putative Female Germline Stem Cells Research in Mammals. Stem Cells Int. 2016;2016:1728278. doi: 10.1155/2016/1728278. Epub 2015 Dec 15. Review.</citation>
    <PMID>26788065</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozakpinar OB, Maurer AM, Ozsavci D. Ovarian stem cells: From basic to clinical applications. World J Stem Cells. 2015 May 26;7(4):757-68. doi: 10.4252/wjsc.v7.i4.757. Review.</citation>
    <PMID>26029346</PMID>
  </results_reference>
  <results_reference>
    <citation>Diamanti-Kandarakis E, Dattilo M, Macut D, Duntas L, Gonos ES, Goulis DG, Gantenbein CK, Kapetanou M, Koukkou E, Lambrinoudaki I, Michalaki M, Eftekhari-Nader S, Pasquali R, Peppa M, Tzanela M, Vassilatou E, Vryonidou A; COMBO ENDO TEAM: 2016. MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview. Eur J Endocrinol. 2017 Jun;176(6):R283-R308. doi: 10.1530/EJE-16-1061. Epub 2017 Mar 6. Review.</citation>
    <PMID>28264815</PMID>
  </results_reference>
  <results_reference>
    <citation>Gat I, Blanco Mejia S, Balakier H, Librach CL, Claessens A, Ryan EA. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gynecol Endocrinol. 2016 Jul;32(7):534-7. doi: 10.3109/09513590.2015.1137095. Epub 2016 Feb 1.</citation>
    <PMID>26829445</PMID>
  </results_reference>
  <results_reference>
    <citation>Özcan P, Fıçıcıoğlu C, Kizilkale O, Yesiladali M, Tok OE, Ozkan F, Esrefoglu M. Can Coenzyme Q10 supplementation protect the ovarian reserve against oxidative damage? J Assist Reprod Genet. 2016 Sep;33(9):1223-30. doi: 10.1007/s10815-016-0751-z. Epub 2016 Jun 3.</citation>
    <PMID>27255570</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fertiaguerrevere</investigator_affiliation>
    <investigator_full_name>Lucy Coleman</investigator_full_name>
    <investigator_title>Scientific director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Still deciding if sharing information. It can be shared as long as it does not contain personal identification such as name, and contact details. We might share the rest of information to other scientist studying the same area of low-depleted ovarian reserve and bio-stimulation techniques.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

